Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6

WBP216 is an innovative IL-6 antibody, presenting high affinity to IL-6 and a long half-life (40–60 days). To optimize the dosage regimen for future clinical trials, pharmacokinetics (PK) and pharmacodynamics (PD) of WBP216 would be firstly characterized in Chinese rheumatoid arthritis (RA) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiange, Zeng, Xiaofeng, Guan, Xiaoduo, Chen, Rui, Hu, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930490/
https://www.ncbi.nlm.nih.gov/pubmed/33679400
http://dx.doi.org/10.3389/fphar.2021.617265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930490/
https://www.ncbi.nlm.nih.gov/pubmed/33679400
http://dx.doi.org/10.3389/fphar.2021.617265

Ejemplares similares